Yamato: Lower SINOPHARM (01099) rating to "hold" with a target price of HK$18.
The company's earnings per share for 2026 to 2028 are expected to increase by 4.5%, 5.6%, and 8.5% respectively compared to the previous year, lower than the market expectation by 3% to 6%.
Daiwa released a research report stating that SINOPHARM (01099) revenue has started to stabilize, but there is no clear rebound timetable yet. Retail pharmacy revenue is expected to grow by double-digits year-on-year in 2026. The rating has been downgraded from "outperform the market" to "hold", with the target price lowered from HK$21 to HK$18. It is expected that earnings per share will increase by 4.5%, 5.6%, and 8.5% respectively in 2026 to 2028, which is 3% to 6% lower than market expectations.
Related Articles
Haier Smart Home (06690) spent 42.288 million yuan on July 24 to repurchase 1.94 million A shares.
SINOPEC CORP (00386) spent 5.184 million yuan on July 24 to repurchase 1 million A shares.
GUSHENGTANG (02273) spent approximately HK$2.2085 million on July 24th to repurchase 77,800 shares.
Haier Smart Home (06690) spent 42.288 million yuan on July 24 to repurchase 1.94 million A shares.
SINOPEC CORP (00386) spent 5.184 million yuan on July 24 to repurchase 1 million A shares.
GUSHENGTANG (02273) spent approximately HK$2.2085 million on July 24th to repurchase 77,800 shares.
RECOMMEND
